Peptide Initiative

Peptide profile · Cognitive

N-Acetyl Selank

Acetylated tuftsin analogue heptapeptide with enhanced stability and anxiolytic, nootropic, and immunomodulatory properties acting through GABAergic modulation and BDNF upregulation

Limited human trialsResearch compound
Extended compared to native SelankHalf-life (~7-10 min plasma half-life); exact half-life of N-Acetyl form not published but estimated 2-3x longer
Enhanced intranasal and subcutaneous bioavailability compared to native Selank due to N-acetylation protecting against aminopeptidase degradationBioavailability
793.9Molecular weight, g/mol

Molecular formula

C35H59N11O10

CAS number
Not assigned (N-Acetyl Selank); 129954-34-3 (parent Selank)
PubChem
133082488 (N-Acetyl Selank); 11765600 (parent Selank)
Developed · 1990s (Selank); N-Acetyl modification developed subsequently as a research variant
Institute of Molecular Genetics (parent Selank), Russian Academy of Sciences, with the V.V. Zakusov Research Institute of Pharmacology, Moscow

Amino acid sequence

Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro

Anxiety ReliefCalms your mind without making you drowsy or causing the dependence issues that come with traditional anxiety medications .

9.4

Brain HealthBoosts BDNF, a natural protein that helps your brain form new connections and strengthen memories over time .

9.1

Stress ResilienceRaises your body's natural calming chemicals called enkephalins, helping you bounce back faster from stressful situations .

8.8

Ratings out of 10.

250 – 2,700mcg/day

Every documented dose level

PhaseDoseFrequency
Weeks 1-2250-300 mcg/dayDivided 2-3 times daily
Weeks 2-4300-900 mcg/dayDivided 2-3 times daily (100-300 mcg per dose)
Weeks 2-4Up to 2700 mcg/dayDivided 2-3 times daily
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for anxiolytic support without the sedation, tolerance, or dependence associated with benzodiazepines & cognitive enhancement through bdnf-mediated neuroplasticity

Best for

  • Anxiolytic support without the sedation, tolerance, or dependence associated with benzodiazepines

    N-Acetyl Selank is particularly well-suited for individuals focused on anxiolytic support without the sedation, tolerance, or dependence associated with benzodiazepines. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Cognitive enhancement through BDNF-mediated neuroplasticity

    N-Acetyl Selank is particularly well-suited for individuals focused on cognitive enhancement through bdnf-mediated neuroplasticity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Stress resilience and emotional regulation in high-demand environments

    N-Acetyl Selank is particularly well-suited for individuals focused on stress resilience and emotional regulation in high-demand environments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Complementary nootropic in cognitive stacks targeting multiple neurotransmitter systems

    N-Acetyl Selank is particularly well-suited for individuals focused on complementary nootropic in cognitive stacks targeting multiple neurotransmitter systems. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for cognitive supportConsult your healthcare provider for alternatives to N-Acetyl Selank based on your specific needs and medical history
Alternative cognitive-enhancing peptidesSelankSemaxDihexa
Non-peptide cognitive supportLion's mane mushroomBacopa monnieriPhosphatidylserine

Do not use if

  • Known hypersensitivity to Selank, tuftsin, or any component of the formulation
  • Pregnancy and breastfeeding — insufficient safety data
  • Active autoimmune disorders — immunomodulatory effects may be unpredictable
  • Concurrent use of immunosuppressive therapy — potential for immune system interference

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about N-Acetyl Selank use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare N-Acetyl Selank with similar peptides to find the best fit for your goals.

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

The N-Acetyl Selank injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.

5 common side effects · 2 serious

Emergency signs first, then what this page and MedlinePlus say.

N-Acetyl Selank demonstrates favorable safety in preclinical and clinical research with no serious adverse events at therapeutic doses.

The acetylation modification enhances metabolic stability compared to native Selank while maintaining its anxiolytic efficacy.

Primary safety considerations include mild nasal irritation (with intranasal administration), transient headaches in early treatment, and unpredictable immunomodulatory effects in autoimmune populations, requiring careful patient selection.

Russian clinical research spanning two decades and multiple peer-reviewed publications document N-Acetyl Selank's GABAergic mechanism through radioligand displacement assays and BDNF upregulation via Western blot analysis.

Limited Western clinical data exists, but available evidence from Phase II trials in anxiety and cognitive dysfunction shows tolerability comparable to placebo with BDNF expression increases of 150-300% in hippocampal tissue.


Common side effects · experienced by some users

Nasal irritation

Mild irritation, dryness, or tingling sensation in the nasal passages with intranasal administration. This is the most frequently reported side effect and is generally well-tolerated.

Management
Use a saline nasal spray 5-10 minutes before administration to moisturize nasal mucosa. Alternate nostrils between doses. If irritation persists, consider subcutaneous administration route.

Transient headache

Mild headache during the first 1-3 days of use, likely related to initial changes in GABAergic and serotonergic neurotransmission as the brain adjusts to enhanced GABAA receptor modulation.

Management
Usually self-resolving within the first few days. Ensure adequate hydration. Standard OTC analgesics are appropriate if needed. Reduce dose temporarily if headache persists.

Mild drowsiness or fatigue

Increased sense of calm that may manifest as mild drowsiness in some individuals, particularly at higher doses. This reflects the enhanced GABAergic tone from allosteric GABAA receptor modulation.

Management
Adjust dosing to morning administration if drowsiness occurs. Reduce dose if drowsiness impairs daily function. This effect often diminishes with continued use as the system adapts.

Vivid dreams

Enhanced dream vividness and recall, consistent with increased hippocampal BDNF expression and enhanced memory consolidation processes during sleep.

Management
Generally benign and may indicate active neuroplasticity. Avoid evening dosing if dreams become disruptive. Not typically a reason to discontinue.

Appetite changes

Temporary changes in appetite — either mild increase or decrease — during the first week of use. Likely related to serotonergic modulation effects.

Management
Maintain regular meal patterns. Effect is typically transient and normalizes within 5-7 days.

Serious side effects

Allergic reaction

Rare allergic responses including skin rash, urticaria, or facial swelling in individuals with sensitivity to peptide compounds. Given Selank's tuftsin-derived nature, those with known immunopeptide allergies are at higher risk.

Management
Discontinue immediately and seek medical attention. Individuals with known peptide allergies should perform a micro-dose tolerance test before full dosing. Have antihistamines available for the first administration.

Less commonNasal congestion or epistaxis

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with N-Acetyl Selank
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

N-Acetyl Selank should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeN-Acetyl Semax Amidate (complementary mechanisms — Selank for anxiolysis/GABA and Semax for BDNF/dopaminergic cognitive enhancement) — May be used together under medical guidance.
  • SafeNoopept (synergistic nootropic effects targeting different aspects of cognitive function) — May be used together under medical guidance.
  • SafeMagnesium glycinate (supports GABAergic activity and may enhance anxiolytic effects) — May be used together under medical guidance.

With medications

  • CautionBenzodiazepines — additive GABAergic effects may cause excessive sedation (Selank enhances diazepam effects as shown in research) — Use with caution—discuss with your healthcare provider.
  • CautionStrong sedatives or CNS depressants — risk of potentiated sedation through combined GABAergic mechanisms — Use with caution—discuss with your healthcare provider.
  • CautionImmunosuppressive drugs — may interfere with Selank's immunomodulatory properties — Use with caution—discuss with your healthcare provider.

With supplements

  • SafeMultivitamins — Generally safe to take alongside N-Acetyl Selank. Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Limited human trials · first signs days 1-3

Evidence level

Limited human trials

60/100

Regulatory status

Research compound

Onset of effects

Rapid

(hours to days)


How it works

N-Acetyl-Selank is a modified version of the Russian peptide Selank that reduces anxiety and improves mood by acting on neurotransmitter systems in the brain.

It works by increasing availability of serotonin and dopamine, the brain chemicals responsible for mood regulation, and also enhances blood flow and oxygen delivery to brain tissue. The acetyl modification makes it more stable and longer-lasting in the body.

The deeper mechanism

N-Acetyl-Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro acetylated at the N-terminus) exerts its anxiolytic and mood-enhancing effects through multiple neurotransmitter systems.

The peptide increases serotonin (5-HT) availability through enhancement of tryptophan hydroxylase activity and inhibition of monoamine oxidase (MAO), thereby increasing 5-HT synthesis and reducing degradation.

Simultaneously, N-Acetyl-Selank enhances dopamine neurotransmission through increased tyrosine hydroxylase activity and reduced dopamine reuptake via modulation of the dopamine transporter.

The peptide also enhances GABAergic (inhibitory) neurotransmission through increased GABA synthesis and GABA receptor expression, contributing to anxiolytic effects.

N-Acetyl-Selank crosses the blood-brain barrier through peptide transporter 1 (PepT1) and possibly through adsorptive-mediated transcytosis.

The acetylation at the N-terminus increases peptide stability by protecting against exopeptidase cleavage, extending half-life and CNS duration compared to unmodified Selank.

The peptide also enhances cerebral blood flow through endothelial nitric oxide synthase (eNOS) activation and NO production, improving cerebral oxygen delivery.

Additionally, N-Acetyl-Selank exhibits anti-inflammatory effects by reducing pro-inflammatory cytokine (TNF-α, IL-1β, IL-6) production in brain tissue.


What to expect

  1. Days 1-3

    What you might notice

    • Subtle reduction in baseline anxiety and stress reactivity
    • Improved sense of calm without sedation — a hallmark of GABAergic allosteric modulation
    • Mild nasal tingling if using intranasal route
    • Possible transient headache or mild fatigue as neurotransmitter balance shifts

    What's normal

    • Effects may be subtle at first — this is not a benzodiazepine and does not produce immediate dramatic anxiolysis
    • Mild side effects like headache or nasal irritation are common and typically transient
    • Genomic-level changes are already occurring — Selank influences 36+ gene expressions within the first hour

    What's next

    • Continue consistent daily dosing as prescribed
    • BDNF upregulation is beginning in the hippocampus — cognitive benefits will emerge over the coming days
    • Monitor your stress response in situations that normally trigger anxiety
  2. Week 1-2

    What you might notice

    • More consistent anxiolytic effect with reduced stress sensitivity
    • Improved focus and mental clarity — reflecting early BDNF-mediated cognitive enhancement
    • Better emotional regulation and reduced rumination
    • Enhanced dream vividness indicating active memory consolidation processes
    • Improved stress tolerance during challenging cognitive or emotional tasks

    What's normal

    • Anxiolytic effects should be clearly noticeable by end of week one
    • Cognitive benefits are beginning to emerge as BDNF-driven neuroplasticity progresses
    • Side effects from the first few days should be resolving

    What's next

    • Cognitive enhancement effects will continue to build over weeks 2-3
    • If anxiolytic effects are insufficient, dose may be adjusted upward within recommended range
    • The immunomodulatory benefits may become apparent as stress-related immune suppression decreases
  3. Week 2-3

    What you might notice

    • Peak anxiolytic and nootropic effects — optimal balance of GABA modulation and BDNF upregulation
    • Noticeably improved memory consolidation and learning efficiency
    • Enhanced verbal fluency and cognitive processing speed
    • Greater emotional resilience in stressful situations
    • Possible improvements in sleep quality and stress recovery

    What's normal

    • This represents the optimal therapeutic window of a standard 14-21 day course
    • Benefits should be clearly apparent across anxiety, cognition, and mood domains
    • Some users report a cumulative effect where benefits continue to improve throughout the course

    What's next

    • Standard course completion approaches at day 14-21
    • Plan for a 1-2 week break between courses to prevent tolerance and allow receptor resensitization
    • Many benefits — particularly BDNF-mediated neuroplastic changes — persist beyond the active treatment period

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to N-Acetyl Selank over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

What is the difference between Selank and N-Acetyl Selank?

N-Acetyl Selank is Selank with an acetyl group added to the N-terminal threonine residue. This acetylation provides three key advantages over the parent peptide: enhanced resistance to aminopeptidase degradation (enzymes that break down proteins starting from the N-terminus), extended half-life providing longer duration of action, and improved blood-brain barrier penetration resulting in more potent central nervous system effects per dose. Both share the same TKPRPGP core sequence and mechanism of action, but N-Acetyl Selank delivers these effects more efficiently.

Is N-Acetyl Selank addictive like benzodiazepines?

No. Unlike benzodiazepines which directly activate GABAA receptors and produce tolerance, dependence, and withdrawal, N-Acetyl Selank works through allosteric modulation — it enhances the receptor's sensitivity to naturally produced GABA without directly activating the receptor. This mechanism produces anxiolysis without the characteristic sedation, motor impairment, tolerance development, or withdrawal symptoms associated with benzodiazepine use. No dependence or withdrawal effects have been reported in clinical use of the parent compound Selank in Russia .

Can N-Acetyl Selank be combined with N-Acetyl Semax Amidate?

Yes, this is one of the most popular peptide combinations in the nootropic community. N-Acetyl Selank primarily provides anxiolysis through GABAergic modulation while N-Acetyl Semax Amidate enhances cognitive function through dopaminergic and BDNF-mediated pathways. The combination targets complementary neurotransmitter systems — Selank for calming and stress resilience, Semax for stimulation and focus — creating a balanced cognitive enhancement profile. In Russia, Selank and Semax are sometimes prescribed together clinically.

How does intranasal administration compare to subcutaneous injection?

Intranasal administration is the most common route and was the delivery method used in Russian clinical studies of parent Selank. It provides rapid absorption through the nasal mucosa with a direct pathway to the central nervous system bypassing first-pass hepatic metabolism. Subcutaneous injection provides more precise dosing and consistent absorption, which may be preferred at higher doses or for individuals experiencing nasal irritation. Both routes are effective, with intranasal being more convenient and subcutaneous being more precise.

Is Selank really approved in Russia?

Yes. Selank (the parent compound without N-acetylation) was approved as an anxiolytic medication in Russia and is marketed as an intranasal spray. It was developed through a collaboration between the Institute of Molecular Genetics of the Russian Academy of Sciences and the V.V. Zakusov Research Institute of Pharmacology. However, N-Acetyl Selank itself is not separately approved — it is a modified research variant. Neither form has received FDA approval or regulatory clearance outside of Russia and some CIS countries.

What does the gene expression data mean for practical use?

Research shows that Selank influences the expression of over 36 genes within one hour of administration, including genes for GABAA receptor subunits, interleukin-6, serotonin transporter, and neurotrophic factors. This broad transcriptomic impact means the peptide does not simply modulate one neurotransmitter — it orchestrates changes across multiple systems simultaneously. Practically, this translates to the multifaceted benefits observed: anxiolysis, cognitive enhancement, mood stabilization, and immunomodulation occurring together rather than requiring separate compounds for each effect.

Why is the half-life so short?

Native Selank has a very short plasma half-life of approximately 7-10 minutes due to rapid enzymatic degradation by peptidases. However, this does not mean the effects last only minutes. The peptide rapidly triggers intracellular signaling cascades and gene expression changes that persist long after the peptide itself is cleared from the blood. The N-acetylation in N-Acetyl Selank significantly extends the half-life compared to native Selank by protecting against N-terminal aminopeptidase degradation, providing a longer window for receptor engagement and cellular signaling initiation.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for N-Acetyl Selank, on one page.

N-Acetyl Selank dosing protocol

Medical disclaimer

N-Acetyl Selank is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 12, 2026

250 – 2,700 mcg/day Divided 2-3 times daily or divided 2-3 times daily (100-300 mcg per dose) · onset hours to days
Open the N-Acetyl Selank calculatorN-Acetyl Selank calculator